DGAP-News

Biotest AG: Biotest increases revenues by 16,6%

DGAP-News: Biotest AG / Key word(s): Quarter Results
Biotest AG: Biotest increases revenues by 16,6%

07.05.2015 / 11:00

---------------------------------------------------------------------

/
PRESS RELEASE

Biotest increases revenues by 16,6%

- Higher Sales in the US

- Capacity expansion at headquarter Dreieich in schedule

Dreieich, 7 May 2015. The Biotest Group again succeeded to increase
revenues in the first three months of 2015. The Group generated revenue of
EUR 142.5 million in the period from January to March 2015. This represents
an increase of 16.6 % compared to the same period in the previous year
(EUR 122.2 million). Sales increased significantly in some areas in the
Plasma & Services (+ 53.5 %) and Therapy (+ 5.7 %) segments.

Substantial revenue increases were achieved in the US, Germany and the
"Other Asia and Pacific" reporting region. Sales of plasma in particular
increased in the US in addition to increased sales of Bivigam(R). Biotest
operates plasma collection centres for long-term cooperation partners who
are active in other market segments.

The Biotest Group is continuing to invest considerable funds in the
development of new products and further development of its existing
products. Operating income (EBIT) decreased from EUR 10.7 million to EUR
0.1 million due to these increased research and development costs, costs
incurred for the capacity expansion already underway, unabsorbed costs at
the US subsidiary, Biotest Pharmaceuticals Corporation (BPC), as well as
sustained price pressure in individual product areas and regions. This
sluggish earnings performance at the beginning of the year has already been
reflected in the 2015 forecast made in March this year.

Increased R&D costs, the unabsorbed costs described above and continued
price pressure in individual product areas and regions resulted in a
negative EBIT, especially in the Therapy segment. Costs of EUR 1.1 million
incurred in connection with the capacity expansion also had a negative
impact on earnings, resulting in the decrease of EBIT for the Therapy
segment to EUR - 6.4 million (same period in the previous year: EUR + 7.1
million). However, EBIT of the Plasma & Services segment increased
significantly by 57.8 % from EUR 4.5 million to EUR 7.1 million. This is
due to the increase in sales of plasma to long-time cooperation partners.

The financial result amounted to EUR 4.1 million (same period in the